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Background: Anti-tumour immune competence has an impact in hepatocarcinogenesis and success of anti-cancer
therapies. Tumour-infiltrating lymphocytes (TILs) and monocytes/macrophages (TAMs) are proposed to have significance
in cancer. However, there is only limited data concerning their impact on patient outcome and survival in hepatocellular
carcinoma (HCC).
Methods: Frequencies of CD68+, CD163+ M2-polarized TAMs and TILs were measured in de novo HCC tumours in non-
cirrhosis (n = 58) using immunohistology and correlated to patients’ clinicopathological characteristics and survival rates.
Results: Patients with tumours marked by appearance of TILs and CD68+ TAMs showed an improved 1-, 3- and 5-year
recurrence-free survival (all p ≤ 0.05). CD68+ TAMs were associated with reduced incidence of recurrent and multifocal
disease. Conversely, CD163+ TAMs were associated with multifocal HCC and lymphangiosis carcinomatosa (all p ≤ 0.05).
Conclusions: TILs and CD68+ TAMs are associated with multiple tumour characteristics and patient survival in HCC.
However, there is only scarce data about the biology underlying their mechanistic involvement in human tumour
progression. Thus, experimental data on functional links might help develop novel immunologic checkpoint inhibitor
targets for liver cancer.
Keywords: Hepatocellular carcinoma, Monocytes/macrophages, Tumour-infiltrating lymphocytes, M2 macrophages,
Biomarkers, PrognosisBackground
Tumour-related mechanisms define the host immune
functions in the tumour microenvironment and decrease
the efficiency of the anti-tumour immune competence.
This phenomenon plays a key role in the process of
hepatocarcinogenesis, where tumour infiltration with
immune competent cells exerts a strong influence on
prognosis [1]. In liver cancer, tumour-associated© The Author(s). 2019 Open Access This artic
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guished functional polarization have a significant impact
on cancer-related inflammation and foster tumour escape
mechanisms and progression [2]. These subpopulations of
immunologic phenotypes are related to as classically (M1)
or alternatively activated (M2) monocytes/macrophages.
These monocytes/macrophages deploy their immunoregu-
latory activities in close interplay with T cell-dependent
responses [2].
Tumour-infiltrating lymphocytes (TILs) play a major
role in the progression of solid malignancies and can
have a strong influence on the success of the related
anti-cancer therapies. TILs in hepatocellular carcinoma
(HCC) are mainly T cells. TILs are the hallmark of the
anti-cancer immunity in human cancer, on grounds ofle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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tumour-related neoantigens [3]. TILs’ immune activity
may influence hepatocarcinogenesis not only by direct ef-
fects on the adaptive immune system and cytokine inter-
actions, but also further by modulating neoangiogenesis
and innate immune responses, i.e. related monocyte/mac-
rophages functions [4–8]. Therefore, the quantification of
TILs in solid tumours might help to deliver novel insights
concerning their role in the process of hepatocarcinogen-
esis and to monitor the therapy outcome with immuno-
logic checkpoint inhibition.
Major progress in the efficacy of adjuvant therapies for
hepatic malignancies has emerged. However, the restraints
of these neoadjuvant regimens constitute an important
clinical problem [9]. Therefore, an additional immune
checkpoint blockade represents an attractive therapeutic
concept that complements these current therapies in can-
cer. Furthermore, the pre- and on-treatment quantifica-
tion of the immunologic infiltrates could deliver novel
biomarkers for state of the art disease management, based
on the fact that immunological checkpoint targeting is
effective only in a scarce amount of the tumour patients
[10]. HCC can arise de novo in non-cirrhotic hepatic
environment in approximately 20% of all cases [11].
However, this subgroup of patients usually presents at an
advanced stage of hepatocarcinogenesis, due to the lack of
symptoms and surveillance. Therefore, our study aimed to
assess the presence and abundance of tumour-infiltrating
subsets of monocytes/macrophages and TILs in advanced
de novo HCC in non-cirrhosis. This study investigated
also their association with tumour recurrence, patient
survival and outcome.
Methods
Patients and tumour specimens
Our retrospective study was conducted in 58 patients with
de novo HCC in non-cirrhosis. In all patients, a major liver
resection with curative intent was performed. None of the
included patients had history of viral hepatitis or were
treated with neoadjuvant radio- and/or chemotherapy
before the tumour resection. Formalin-fixed and paraffin-
embedded surgical specimens, embedding a representative
tumour sample for immunohistochemical staining, were
obtained from the archives of the Department of Pathology.
The study was conducted in accordance with the ethical
guidelines of the Declaration of Helsinki and was approved
by the Ethics Committee of the Leipzig University.Table 1 Antibodies and reagents used for immunostaining
Antigen m/p Clone Species Company Seco
CD68 m PG-M1 Mouse Agilent anti-
CD163 m 10D6 Mouse Leica Biosystems, Newcastle
Upon Tyne, UK
anti-
DAB 3,3′-diaminobenzidine, m monoclonal, p polyclonal, TAM tumor-associated macImmunohistology
The protocols for immunohistology and quantification
of positive staining have been published previously [12–
16]. The abundance of infiltrating TILs, CD68+ and
CD163+ TAMs were measured in regard to the tumour
central area (TCA) and the tumour-infiltrating front
(TIF). Zeiss Axio Imager A1 Phase Contrast microscope
(Carl Zeiss, Jena, Germany) was used to asses positive
staining. Table 1 summarizes the antibodies and reagents
used to conduct immunohistology.
Density quantification of cellular infiltrates
Quantification was performed as described [13]. In brief,
tumour-infiltrating immune cells were categorized as nega-
tive/absent in up to 5% positive cells (0–5% positive cells,
score 0) and positive/present (> 5% positive cells, score 1).
HCC patients were then assigned to two groups either to
be negative or positive for CD68+ or CD163+ TAMs. Evalu-
ation of TILs was performed using routine H&E slides as
described [17]. Briefly, the extent of lymphocyte abundance
in the tumour area was categorized as none (score 0), low
(score 1), moderate (score 2) or high (score 3). Accordingly,
HCC patients were then assigned to the TIL− (none to low
infiltration) or TIL+ group (moderate to high infiltration).
Statistical analysis
The IBM SPSS statistics software was used to perform
survival and univariate analysis and to produce the
Kaplan-Meier curves (Version 25/Year 2017/USA). The
log-rank test was applied to compare differences in sur-
vival distributions. The Cox proportional hazards model
was utilized to conduct multivariate analysis for the
significant parameters in the univariate analysis. The
chi-square test, Fisher’s exact test or Student’s t test (in-
dependent sample) were applied to compare categorical
and continuous variables. Statistical differences were
considered significant for p ≤ 0.05.
Results
Table 2 summarizes the clinicopathological characteris-
tics of all patients included in the current work. The
studied population of HCC patients had 1-, 3- and 5-
year survival of 76.4%, 64.1% and 62.2%, respectively.
The recurrence-free survival rates 1-, 3- and 5- year
after tumour resection were 63.5%, 57.7% and 53.6%,
respectively. In 23/58 (39.7%) patients, a recurrent
tumour disease was detected and 17/58 (29.3%) patientsndary antibody Company Substrate Antigen retrieval
mouse-Ig/ peroxidase Vector DAB Tris/EDTA pH 9.0
mouse-Ig/ peroxidase Vector DAB 10 mM citrate, pH 5.5
rophage
Table 2 Clinicopathological characteristics of the patients
included in the study
Variable Value (%)





≤ 60 21 (36.2%)

















≤ 50 11 (19.0%)
















Atanasov et al. World Journal of Surgical Oncology           (2019) 17:97 Page 3 of 8developed a local tumour recurrence. A metastatic dis-
ease was seen in 11/58 (19.0%) patients.Distribution of monocytes/macrophages and tumour-
infiltrating lymphocytes in HCC
Figure 1 provides characteristic images for the abundance
of TILs and CD68+ or CD163+ TAMs in HCC. Tables 2,
3, 4 and 5 summarize the respective statistical data of the
patients. TILs and CD68+ or CD163+ TAMs revealed a
homogeneous expression pattern in TCA and TIF and
were also detected in areas of HCC necrosis (Fig. 1a–f ).Monocytes/macrophages are associated with reduced
incidence of tumour recurrence and formation of multiple
tumour nodules in HCC patients
CD68+ TAMs in TIF were associated with reduced occur-
rence of recurrent HCC. In the CD68+ group, only 19/53
(35.8%) patients suffered overall tumour recurrence,
whereas in the CD68− group, 4/5 (80.0%) patients had
recurrent disease (p = 0.05; Table 3). CD68+ TAMs in TIF
were also correlated with reduced formation of multiple
tumour nodules (p = 0.035). In the CD68+ group, only 10/
53 (18.9%) patients showed this feature, whereas in the
CD68− group, these were 2/5 (40.0%) patients (p = 0.035).M2-polarized macrophages are associated with
lymphangiosis carcinomatosa and formation of multiple
tumour nodules in HCC patients
CD163+ TAMs in TCA were associated with the forma-
tion of multiple tumour nodules (p = 0.016; Table 4). In
the CD163+ group, 36/42 (85.7%) patients had multiple
tumour nodules; in the CD163− group in 9/16 (56.3%)
patients, this was diagnosed (p = 0.016). Moreover, when
considering the TIF, in the CD163− group, 31/39 (79.5%)
patients had absence of lymphangiosis carcinomatosa. In
the CD163+ group, these were 10/19 (52.6%) patients
(p = 0.035). No significant association between CD163+
TAMs in TCA or TIF with CD68+ TAMs could be
detected.Tumour-infiltrating lymphocytes are associated with
intratumoural monocytes/macrophages in HCC patients
TILs in TCA or TIF were not correlated with clinico-
pathological features of HCC patients (Table 5). How-
ever, in regard to the TCA, TILs and CD68+ TAMs
revealed a strong correlation. In the TIL+ group in 20/20
(100%) and in the TIL− group in only 11/38 (28.9%) pa-
tients, high frequencies of CD68+ TAMs were detected
(p = 0.008). No significant correlations between TILs in
TCA or TIF with CD163+ TAMs could be observed.
Fig. 1 Immunohistology of monocytes/macrophages and H&E staining of TILs in tumour central area (TCA) of HCC specimens. a High density of
CD68+ TAMs. b Low density of CD68+ TAMs. c High density of CD163+ TAMs. d Low density of CD163+ TAMs. e High density of TILs. f Low
density of TILs. Legend: left column, high density; right column, low density. Black arrows indicate monocytes/macrophages, white arrows TILs
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infiltrating lymphocytes on survival in HCC patients
In our study, CD68+ TAMs and TILs were associated with
patients’ recurrence-free survival. Figure 2 shows the
Kaplan-Meier survival curves. Tables 2, 3, 4 and 5 show the
statistical evaluation of all patients. Recurrence-free survival
rates were significantly improved in patients with TILs in
TCA (Fig. 2a). One, 3 and 5 years after surgery, these were
68.9%, 63.9% and 61.6%, respectively. Conversely, the sur-
vival was 37.8%, 23.4% and 23.4% at 1, 3 and 5 years post-
surgery, respectively, in patients without TILs in TCA (p =
0.05). Similar data was obtained in regard to CD68+ TAMs
in TIF (Fig. 2b). The recurrence-free survival rates were
66.9%, 63.3% and 60.0% at 1, 3 and 5 years for patients withCD68+ TAMs in TIF. Contrarily, the recurrence-free sur-
vival was 28.7% at 1 year post-surgery in HCC patients
without these cells in the TIF. Of note, survival beyond 3
years after surgery could not be reached in patients without
CD68+ TAMs in TIF (p = 0.04). CD163+ TAMs in TCA or
TIF did not reveal any significant correlation with overall
or recurrence-free survival of the HCC patients (CD163+
TAMs in TCA: overall survival p = 0.858, recurrence-free
survival p = 0.283; CD163+ TAMs in TIF: overall survival
p = 0.410, recurrence-free survival p = 0.405).
Discussion
In the present work, we determined the level of abun-
dance of monocytes/macrophages and TILs in tumour
Table 3 Correlation of CD68+ TAMs at the tumour-infiltrating
front (TIF) with clinicopathological characteristics in HCC
Variable CD68+/TIF CD68−/TIF p value
No. of patients 53 5
Patient age, years 0.324
≤ 60 33 (62.3%) 4 (80.0%)
> 60 20 (37.7%) 1 (20.0%)
Gender 0.430
Female 42 (79.2%) 3 (60.0%)
Male 11 (20.8%) 2 (40.0%)
Local tumour recurrence 0.583
Positive 15 (28.3%) 2 (40.0%)
Negative 38 (71.7%) 3 (60.0%)
Overall tumour recurrence 0.050
Positive 19 (35.8%) 4 (80.0%)
Negative 34 (64.2%) 1 (20.0%)
Distant Metastases 0.209
Positive 9 (17.0%) 2 (40.0%)
Negative 44 (83.0%) 3 (60.0%)
Multiple tumour nodules 0.035
Positive 10 (18.9%) 2 (40.0%)
Negative 43 (81.1%) 3 (60.0%)
Tumour size (mm) 0.951
≤ 50 10 (10.0%) 1 (20.0%)
> 50 43 (90.0%) 4 (80.0%)
R status 0.772
Positive 8 (15.1%) 1 (20.0%)
Negative 45 (84.9%) 4 (80.0%)
Angioinvasion 0.583
Positive 25 (47.2%) 2 (40.0%)
Negative 28 (52.8%) 3 (60.0%)
Lymphangiosis carcinomatosa 0.583
Positive 15 (28.3%) 2 (40.0%)
Negative 38 (71.8%) 3 (60.0%)
Histologic differentiation 0.951
Well 10 (10.0%) 1 (20.0%)
Moderate/poor 43 (90.0%) 4 (80.0%)
Pathologic T stage 0.148
T1/T2 28 (53.8%) 1 (20.0%)
T3/T4 24 (46.2%) 4 (80.0%)
Pathologic N stage 0.658
Positive 2 (03.8%) 0 (00.0%)
Negative 51 (96.2%) 5 (100.0%)
Table 4 Correlation CD163+ TAMs in the tumour central area
(TCA) or tumour-infiltrating front (TIF) with clinicopathological
characteristics in HCC
Variable CD163+/TCA CD163−/TCA p value
No. of patients 42 16
Patient age, years 0.177
≤ 60 13 (31.0%) 8 (50.0%)
> 60 29 (69.9%) 8 (50.0%)
Gender 0.680
Female 10 (76.2%) 3 (18.8%)
Male 32 (23.8%) 13 (81.2%)
Local tumour recurrence 0.398
Positive 11 (26.2%) 6 (37.5%)
Negative 31 (73.8%) 10 (62.5%)
Overall tumour recurrence 0.320
Positive 15 (35.7%) 8 (50.0%)
Negative 27 (64.3%) 8 (50.0%)
Distant metastases 0.469
Positive 7 (16.7%) 4 (25.0%)
Negative 35 (83.3%) 12 (75.0%)
Multiple tumour nodules 0.016
Positive 36 (85.7%) 9 (56.3%)
Negative 6 (14.3%) 7 (43.8%)
Tumour size (mm) 0.438
≤ 50 9 (21.4%) 2 (12.5%)
> 50 33 (78.6%) 14 (87.5%)
R status 0.695
Positive 35 (15.1%) 2 (12.5%)
Negative 7 (84.9%) 14 (87.5%)
Angioinvasion 0.311
Positive 20 (47.6%) 10 (62.5%)
Negative 22 (52.4%) 6 (37.5%)
Lymphangiosis carcinomatosa 0.656
Positive 13 (31.0%) 4 (25.0%)
Negative 29 (69.0%) 12 (75.0%)
Histologic differentiation 0.979
Well 8 (19.0%) 3 (18.8%)
Moderate/poor 34 (81.0%) 13 (81.3%)
Pathologic T stage 0.501
T1/T2 22 (53.7%) 7 (43.8%)
T3/T4 19 (46.3%) 9 (56.3%)
Pathologic N stage 0.470
Positive 1 (02.4%) 1 (06.3%)
Negative 41 (97.6%) 15 (93.7%)
No. of patients 19 39
Lymphangiosis carcinomatosa 0.035
Positive 9 (47.4%) 8 (20.5%)
Negative 10 (52.6%) 31 (79.5%)
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Table 5 Correlation of TILs in the tumour central area (TCA)
with clinicopathological characteristics in HCC
Variable TIL+/TCA TIL−/TCA p value
No. of patients 20 38
Patient age, years 0.476
≤ 60 6 (30.0%) 15 (39.1%)
> 60 14 (70.0%) 23 (60.9%)
Gender 0.732
Female 15 (75.0%) 30 (78.9%)
Male 5 (25.0%) 8 (21.1%)
Local tumour recurrence 0.933
Positive 6 (30.0%) 11 (28.9%)
Negative 14 (70.0%) 27 (71.1%)
Overall tumour recurrence 0.546
Positive 9 (45.0%) 14 (36.8%)
Negative 11 (55.0%) 24 (63.2%)
Metastases 0.884
Positive 4 (20.0%) 7 (18.4%)
Negative 16 (80.0%) 31 (81.6%)
Multiple tumour nodules 0.100
Positive 18 (90.0%) 27 (71.1%)
Negative 2 (10.0%) 11 (28.9%)
Tumour size (mm) 0.206
≤ 50 2 (10.0%) 9 (23.7%)
> 50 18 (90.0%) 29 (76.3%)
R status 0.148
Positive 15 (75.0%) 34 (89.5%)
Negative 5 (25.0%) 4 (10.5%)
Angioinvasion 0.717
Positive 11 (55.0%) 19 (50.0%)
Negative 9 (45.0%) 19 (50.0%)
Lymphangiosis carcinomatosa 0.057
Positive 9 (45.0%) 30 (78.9%)
Negative 11 (45.0%) 8 (21.1%)
Histologic differentiation 0.576
Well 3 (15.0%) 8 (21.1%)
Moderate/poor 17 (85.0%) 30 (78.9%)
Pathologic T stage 0.708
T1/T2 9 (47.4%) 20 (52.6%)
T3/T4 10 (52.6%) 18 (47.4%)
Pathologic N stage 0.296
Positive 0 (00.0%) 2 (5.3%)
Negative 20 (100.0%) 36 (94.7%)
CD68+ TAMs/TCA 0.008
Positive 20 (100.0%) 11 (28.9%)
Negative 0 (00.0%) 27 (71.1%)
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cirrhosis after oncologic resection. In addition, their as-
sociation with patient’ clinicopathologic characteristics
and survival was analysed. The major discoveries were
(1) CD68+ TAMs were associated with decreased rates
of recurrent and multifocal disease; (2) conversely, M2-
polarized TAMs correlated with lymphangiosis carcino-
matosa and multifocal HCC; (3) TILs and infiltrating
CD68+ TAMs were strongly associated in HCC; and (4)
had a potent influence on recurrence-free survival.
In this study, we demonstrated that CD68+ TAMs and
M2-polarized TAMs correlate with established clinicopath-
ologic features of advanced de novo HCC in non-cirrhosis.
Of note, 29/58 (50%) of the HCC patients in our study had
T3/T4 tumours and 47/58 (81%) tumours exhibited moder-
ate/poor histologic differentiation. These results are in
accordance with previously published results in HCC and
other hepatobiliary tumours, which report on a negative
impact of M2 polarization state of infiltrating TAMs on pa-
tient survival and outcome [18, 19]. However, when consid-
ering CD68+ TAMs, most published results demonstrate a
negative value in regard to patient outcome [20]. Here,
CD68+ TAMs were associated with significantly prolonged
survival. A possible scenario for our results could be that
TAMs comprise a diverse and heterogeneous cell popula-
tion which can express markers typical not only for M1 or
M2 polarization states. Their functionality strongly de-
pends on the signals deployed by the tumour microenvir-
onment, i.e. TAMs re-education and reprogramming as
classical tumour escape mechanisms. In line with this, Li
et al. demonstrated CD68+ TAMs to be also CD204+ or
CD169+ cells. The tissue frequency of CD204+ TAMs
associated with poor outcome. Conversely, CD169+ TAMs
were associated with better survival [19]. Insofar, add-
itional research is needed to investigate the mechanistic
interplay between diverse TAMs subpopulations and the
tumour microenvironment.
The predominant immune cell population in the tumour
vicinity consists mainly of TILs. Accumulating scientific
data demonstrates that the type, density and localization of
host immunologic tumour infiltration influence its malig-
nant behaviour and could provide clinically informative
prognostic biomarkers [21–23]. Furthermore, this im-
munologic reaction could characterize patient outcome to
a greater extent than the diagnostics for the staging of can-
cer, which are currently applied by conventional histopath-
ology [24]. Consequently, TILs were identified as a reliable
immunologic tool in the tumour microenvironment that
could be used in clinical trials and translational research.
Insofar, here we focused on the prognostic capacity of TILs
in tumour specimens of HCC. Our findings indicate that
the presence of TILs significantly influence survival of
HCC patients after curative surgery. Of note, in our work,
intratumoural prevalence of TILs in liver cancer was
Fig. 2 a Recurrence-free survival for TILs in the TCA. TIL− refers to the TIL- group. TIL+ refers to the TIL+ group. b Recurrence-free survival for
CD68+ TAMs in the TIF. CD68+ TAM− refers to the CD68− group. CD68+ TAM+ refers to the CD68+ group.
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it appears possible that infiltrating hepatic monocytes/mac-
rophages and TILs comprise a coherent immunological
construct that exerts a significant impact in the process of
hepatocarcinogenesis.
In our work, in the setting of oncologic HCC resec-
tion, TILs and CD68+ TAMs were associated with better
survival rates, which is in line with most published data
about TILs’ importance in solid cancer that delineates
their presence or high tumour density to be associated
with improved patient survival [17, 25–27]. Insofar, in
this study, we suggest TILs and CD68+ TAMs to be reli-
able cancer biomarkers prognosticating survival and out-
come of HCC patients after surgery. However, a possible
limitation of the current work is the descriptive nature
of our results and the small number of HCC patients
with de novo HCC in non-cirrhosis.Conclusions
Our study demonstrates that TILs, infiltrating monocytes/
macrophages and their functional polarization state asso-
ciate with multiple tumour characteristics and patient
survival in HCC. However, there is only scarce data about
the biology underlying mechanistic involvement of TILs,
monocytes/macrophages and their polarization in M1 or
M2 subtypes in human tumour progression. Thus, a fur-
ther examination of underlying functional mechanisms
that might help develop novel immunologic checkpoint
inhibitor targets for liver cancer is warranted.
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